A Prospective, Open Study on the Safety and Effectiveness of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology) on Healthy Subjects
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Suisselle
- Enrollment
- 41
- Locations
- 1
- Primary Endpoint
- Change from baseline of epidermis hydration higher than 2 AU
Overview
Brief Summary
The current post-market clinical investigation has been designed to evaluate the efficacy and safety of CELLBOOSTER® Lift, a HA-based product marketed by SUISSELLE SA. For this purpose, healthy subjects with signs of skin aging with mild to moderate wrinkles, skin laxity, dry and dull skin on the face, received a 3-session treatment and were followed-up over a 4-month period after the initial injection.
Several objective measurements of skin quality were performed with different parameters: skin elasticity, density, dryness, microcirculation, wrinkles, color/homogeneity. Clinical improvement was also evaluated, as well as subject and investigator satisfactions.
The safety of the injections was also followed with injection site reactions and adverse events collection.
Detailed Description
With age and UV exposure, skin undergoes morphologic and mechanical changes that manifest as wrinkling, sagging, loss of elasticity and dryness. In particular, decreased synthesis of collagen and elastin and their increased degradation reduced proliferative capacity of fibroblasts. Moreover, the perturbations in the organisation of elastic fibre network lead to alterations in the mechanical properties of the skin with reduced resilience and elasticity. Advances in the knowledge of the biochemical mechanisms associated with ageing have led to the development of different approaches to reduce and repair its untoward effects, particularly by using minimally invasive procedures. Originally developed to treat vascular and lymphatic disorders, mesotherapy has recently been used for skin rejuvenation.
Mesotherapy consists of the stimulation of skin biorejuvenation via minimally invasive epidermis or intradermal injections of biologically active substances. The injected ingredients are released over a prolonged period of time into the surrounding tissues, with a depot-like effect. Among the products available for skin rejuvenation by mesotherapy, hyaluronic acid (HA) plays an important role in the moisturization due to its high ability to attract water molecules. Given all the above, HA was a clear natural candidate for such applications, and non-crosslinked HA gels are by far the most popular compounds employed for mesotherapy, both alone and in combination with other molecules. Mesotherapy with HA aids in restoring cutaneous metabolic function, water retention and elasticity, with an altogether improvement in the visible signs of photoaging. The efficacy of non-crosslinked HA injections for the treatment of photoaged skin has been widely reported.
HA-based injections may be supplemented with other active ingredients for additional, synergistic benefits, on condition the compounds be biocompatible and absorbable, such as vitamins, antioxidants and/or amino acids.
Clinical experience of skin rejuvenation by HA-based mesotherapy suggests this technique is safe inasmuch as it is performed by a trained physician, who follows safe-injection practices with appropriate aseptic techniques to prevent, among other, the risk of infection related to inadequate safety measures. Furthermore, several studies suggest mesotherapy can improve skin hydration, firmness and viscoelastic properties. Usually, this type of treatment includes an intensive course with 3 treatments with 2-3 weeks interval, followed by a support course with one treatment per month. The number of treatments needed will depend on the patients (age, skin condition, answer to initial treatment,....).
SUISSELLE has marketed in 2021 the HA-based product CELLBOOSTER® Lift (CBL). CBL consists in a stabilized HA complex with amino acids and vitamins for injection in the epidermis or dermis.
The current post-market clinical investigation is designed to evaluate the efficacy and safety of CBL. For this purpose, healthy subjects with signs of skin aging with mild to moderate wrinkles, skin laxity, dry and dull skin on the face, received a 3-session treatment and were followed-up over a 4-month period after the initial injection.
Several objective measurements of skin quality were performed with different parameters: skin elasticity, density, dryness, microcirculation, wrinkles, color/homogeneity. Clinical improvement was also evaluated, as well as subject and investigator satisfactions.
The safety of the injections was also followed with injection site reactions and adverse events collection.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 35 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Caucasian
- •Phototype II to III
- •Subject with signs of cutaneous ageing on the face with mild to moderate wrinkles, skin laxity, dry and dull skin on face.
- •Subject with a skin hydration rate on cheekbones \< 60 UA, measured with Corneometer®.
- •Subject looking for an improvement using an aesthetic procedure.
- •Subject willing to abstain from other facial aesthetic procedure in the full face through the entire study duration.
- •Subject having given their free, express, and informed consent.
- •Subject psychologically able to understand the information related to the study, and to give their written informed consent.
- •Subject registered with a social security scheme.
- •Female of childbearing potential must use a medically accepted contraceptive method since at least 12 weeks before the beginning of the study and throughout the study.
Exclusion Criteria
- •Pregnant or nursing woman or planning a pregnancy during the study.
- •Woman menopaused from less than 1 year or in perimenopause, without hormonal treatment.
- •Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
- •Subject in a social or sanitary establishment.
- •Subject participating to another research on human beings or being in an exclusion period for a previous study.
- •Subject having received a total of 4.500 euros as compensations for their participation in research involving human beings in the last 12 months, including their participation in the present study.
- •Intensive exposure to sunlight or UV-rays within the previous month and/or planning to do so during the study.
- •Subject with a tattoo, a scar, moles or too many hairs or anything on the face which may interfere with the study at the investigator appreciation.
- •Subject having resorbable filling product (e.g., hyaluronic acid) injections, a laser treatment, an ultrasound-based treatment, a dermabrasion, a deep chemical peeling or other ablative procedure on the face within the past 12 months prior to study start and a facial surgery in the past 2 years
- •Subjects having received botulinum toxin in the face within the 9 previous months.
Outcomes
Primary Outcomes
Change from baseline of epidermis hydration higher than 2 AU
Time Frame: Baseline, Day 42
Measured with a Corneometer®
Secondary Outcomes
- Change from baseline of cutaneous firmness(Baseline, Day 42 and Day 84)
- Change from baseline of skin color parameters(Baseline, Day 42 and Day 84)
- Degree of satisfaction of the subjects(Baseline, Day 42 and Day 84)
- Change from baseline of the elasticity(Baseline, Day 42 and Day 84)
- Percentage of subjects with a GAIS score "improved", "much improved", or "very much improved" (investigator)(Baseline, Day 42 and Day 84)
- Change from baseline of the tonicity(Baseline, Day 42 and Day 84)
- Change from baseline of skin density(Baseline, Day 42 and Day 84)
- Change from baseline of skin microcirculation(Baseline, Day 42 and Day 84)
- Change from baseline of skin wrinkles parameters(Baseline, Day 42 and Day 84)
- Degree of satisfaction of the injectors(After each injection (Day 0, Day 14 and Day 28))
- Change from baseline of epidermis hydration(Baseline, Day 84)
- Change from baseline of the suppleness(Baseline, Day 42 and Day 84)
- Percentage of subjects with a GAIS score "improved", "much improved", or "very much improved" (subjects)(Baseline, Day 42 and Day 84)